Table 1 Patient profiles
| Â | Primary cohort | Â | External validation cohort | Â | ||
|---|---|---|---|---|---|---|
Positive ALN (n = 156) | Negative ALN (n = 234) | P* value | Positive ALN (n = 49) | Negative ALN (n = 97) | P value | |
Age(yrs) | 51.31 ± 10.634 | 52.44 ± 10.596 | 0.302 | 49.09 ± 10.071 | 54.38 ± 9.573 | 0.003 |
BI-RADS categories (%) | Â | Â | 0.000 | Â | Â | 0.129 |
3 | 6(3.8%) | 14(6.4%) | Â | 0(0.0%) | 2(2.1%) | Â |
4a | 9(5.8%) | 9(4.1%) | Â | 4 (8.2%) | 10(10.3%) | Â |
4b | 18(11.5%) | 34(15.5%) | Â | 6(12.2%) | 28(28.9%) | Â |
4c | 27(17.3%) | 66(30.1%) | Â | 15(30.6%) | 26(26.8%) | Â |
5 | 96(61.5%) | 96(43.8%) | Â | 24(49.0%) | 31(32.0%) | Â |
Histological grade (%) | Â | Â | 0.433 | Â | Â | 0.802 |
/ | 33(21.2%) | 53(22.6%) | Â | 6(12.2%) | 14(14.4%) | Â |
1 | 14(9.0%) | 33(14.1%) | Â | 1(2.0%) | 2(2.1%) | Â |
2 | 78(50.0%) | 107(45.2%) | Â | 14(28.6%) | 32(33.0%) | Â |
3 | 31(19.9%) | 41(17.5%) | Â | 28(57.1%) | 49(50.5%) | Â |
Estrogenic receptor (%) | ||||||
+ | 111(71.2%) | 168(71.8%) | 0.909 | 35(71.4%) | 63(64.9%) | 0.276 |
- | 45(28.8%) | 66(28.2%) | 14(28.6%) | 34(35.1%) | ||
Progesterone receptor (%) | ||||||
+ | 98(62.8%) | 146(59.8%) | 0.600 | 32(65.3%) | 57(58.8%) | 0.477 |
- | 58(37.2%) | 98(40.2%) | 17(34.7%) | 40(41.2%) | ||
HER-2 (%) | Â | Â | Â | Â | Â | Â |
+ | 50(32.1%) | 71(30.3%) | 0.738 | 28(57.1%) | 44(45.4%) | 0.220 |
- | 106(67.9%) | 163(69.7%) | 21(42.9%) | 53(54.6%) | ||
Ki-67 status (%) | ||||||
>20% | 119(76.3%) | 141(60.3%) | 0.001 | 46(93.9%) | 77(79.4%) | 0.029 |
≤ 20% | 37(23.7%) | 93(39.7%) | 3(6.1%) | 20(20.6%) | ||
Molecular subtype (%) | ||||||
Luminal A | 29(18.6%) | 73(31.2%) | 0.022 | 4(8.2%) | 8(8.2%) | 0.687 |
Luminal B | 89(57.1%) | 101(43.2%) | 28(57.1%) | 57(58.8%) | ||
HER2 positive | 19(12.2%) | 29(12.4%) | 14(28.6%) | 21(21.6%) | ||
TNBC | 19(12.2%) | 31(13.2%) | 3(6.1%) | 11(11.3%) | ||